Quick Answer
Jasper Therapeutics, Inc. reported Net Income Loss of -$75.80 million for the year ending 2025.
- Jasper Therapeutics, Inc. showed a decrease of -6.4% in Net Income Loss from 2024 to 2025.
- This data is from Jasper Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: -$1.0 thousand | Q1 2020: $1.43 million | Q2 2020: -$3.43 million | Q3 2020: -$201.2 thousand | Q1 2021: -$9.75 million | Q2 2021: -$8.41 million | Q3 2021: -$3.41 million | Q1 2022: -$2.21 million | Q2 2022: -$10.40 million | Q3 2022: -$11.86 million | Q1 2023: -$14.26 million | Q2 2023: -$16.08 million | Q3 2023: -$17.54 million | Q3 2023: -$47.88 million | Q1 2024: -$13.73 million | Q2 2024: -$14.58 million | Q3 2024: -$18.64 million | Q1 2025: -$21.24 million | Q2 2025: -$26.72 million | Q3 2025: -$18.74 million.
- Over the full 6 years of available data (2020 to 2025), Jasper Therapeutics, Inc.'s Net Income Loss has declined by 139.4%.
- Historical annual values: Fiscal year 2025: -$75.80 million | Fiscal year 2024: -$71.27 million | Fiscal year 2023: -$64.47 million | Fiscal year 2022: -$37.69 million | Fiscal year 2021: -$30.64 million | Fiscal year 2020: -$31.67 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: